| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| Other Sizes |
| Targets |
Calmodulin (CaM).
|
|---|---|
| ln Vitro |
Ophiobolin A is a calmodulin antagonist that acts by inhibiting calmodulin action in calcium regulation. It has been shown to inhibit the growth of cancer cells by inducing apoptosis and inhibiting cell proliferation. Ophiobolin A is the dominant member of a class of phytotoxic metabolites produced by plant pathogenic fungi. Specific IC50 values for calmodulin inhibition and anticancer activity are available in the primary literature. The compound has a molecular formula of C25H36O4 and a molecular weight of 400.6 g/mol.
|
| ln Vivo |
In vivo efficacy of ophiobolin A has been studied in animal models of cancer. As a calmodulin antagonist with anticancer activity, it has shown the ability to inhibit tumor growth by inducing apoptosis and inhibiting cell proliferation. Specific dosing regimens and detailed efficacy data are available in the primary literature. The compound has also been studied for its phytotoxic and antifungal activities.
|
| Enzyme Assay |
Calmodulin binding is assessed using in vitro binding assays with calmodulin and a fluorescent or radiolabeled ligand. Calmodulin antagonist activity is assessed by measuring the inhibition of calmodulin-dependent enzyme activities, such as calmodulin-dependent phosphodiesterase or myosin light chain kinase. IC50 values are calculated from dose-response curves. Anticancer activity is assessed in cell-based assays.
|
| Cell Assay |
Cellular activity is evaluated in cancer cell lines. Cells are treated with ophiobolin A at various concentrations (typically 0.1-100 µM) for 24-72 hours. Cell proliferation is measured by MTT, MTS, or CellTiter-Glo assays. Apoptosis is measured by caspase-3/7 activation, Annexin V staining, or PARP cleavage. Cell cycle distribution is analyzed by flow cytometry. Calcium signaling may be assessed using fluorescent calcium indicators.
|
| Animal Protocol |
In vivo efficacy is studied in mouse xenograft models of cancer. Ophiobolin A is administered via various routes (intraperitoneal, intravenous) at doses determined from pharmacokinetic and tolerability studies. Tumor growth is measured by caliper twice weekly, and tumor volume is calculated. Apoptosis and cell proliferation markers are assessed in tumor tissue by immunohistochemistry. Pharmacodynamic markers including calmodulin binding and calcium signaling are assessed.
|
| ADME/Pharmacokinetics |
Ophiobolin A has a molecular formula of C25H36O4 and a molecular weight of 400.6 g/mol. CAS Number: 4611-05-6. Purity: ≥95%. The compound is a natural product sesterterpenoid. It is soluble in DMF, DMSO, ethanol, and methanol. Storage: -20°C. Appearance: A solid. The compound is a phytotoxic metabolite from fungi.
|
| Toxicity/Toxicokinetics |
Safety data for ophiobolin A indicate it is a research compound for laboratory use only. As a calmodulin antagonist with anticancer activity, it may have effects on calcium signaling in various cell types. The compound is a phytotoxin and should be handled with appropriate safety precautions. It is for research use only and not for human therapeutic applications without appropriate regulatory approval. Standard laboratory safety practices should be followed, including the use of personal protective equipment and adequate ventilation.
|
| References | |
| Additional Infomation |
Ophiobolin A is a sesquiterpene compound belonging to the spathone class. It has a hydroxyl group at position 3, carbonyl groups at positions 5 and 25, double bonds at positions 7-8 and 19-20, and an oxygen bond between positions 14 and 18. It is an oxaspirocyclic compound, an enal, a cyclic ketone, a tertiary alcohol, and a sesquiterpene. It is derived from the hydride of spathone compounds. Ophiobolin A has been reported to exist in Bipolaris sorghicola, Bipolaris cookei, and other organisms with relevant data.
Ophiobolin A is a research tool compound for studying calmodulin function, calcium signaling, and anticancer mechanisms. It is not approved for clinical use. The compound is a natural product sesterterpenoid produced by plant pathogenic fungi. Ophiobolin A has been investigated for its potential anticancer activity due to its ability to inhibit calmodulin and induce apoptosis in cancer cells. It is also studied for its phytotoxic and antifungal activities. Ophiobolin A is a valuable tool for understanding the role of calmodulin in cell proliferation and survival and for identifying new therapeutic targets in cancer. |
| Molecular Formula |
C25H36O4
|
|---|---|
| Molecular Weight |
400.55
|
| Exact Mass |
400.261
|
| CAS # |
4611-05-6
|
| PubChem CID |
5281387
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
539.4±50.0 °C at 760 mmHg
|
| Flash Point |
177.8±23.6 °C
|
| Vapour Pressure |
0.0±3.3 mmHg at 25°C
|
| Index of Refraction |
1.554
|
| LogP |
3.75
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
29
|
| Complexity |
778
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
C[C@H]1C[C@@H](O[C@@]12CC[C@]3([C@H]2C/C=C(\[C@@H]4[C@H](C3)[C@](CC4=O)(C)O)/C=O)C)C=C(C)C
|
| InChi Key |
MWYYLZRWWNBROW-BDZRSQQBSA-N
|
| InChi Code |
InChI=1S/C25H36O4/c1-15(2)10-18-11-16(3)25(29-18)9-8-23(4)12-19-22(20(27)13-24(19,5)28)17(14-26)6-7-21(23)25/h6,10,14,16,18-19,21-22,28H,7-9,11-13H2,1-5H3/b17-6-/t16-,18-,19-,21+,22+,23+,24+,25-/m0/s1
|
| Chemical Name |
(1'R,2S,3S,3'S,4'R,5R,7'S,8'E,11'R)-4'-hydroxy-1',3,4'-trimethyl-5-(2-methylprop-1-enyl)-6'-oxospiro[oxolane-2,12'-tricyclo[9.3.0.03,7]tetradec-8-ene]-8'-carbaldehyde
|
| Synonyms |
Cochliobolin A Ophiobolin-A Ophiobolin A
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4966 mL | 12.4828 mL | 24.9657 mL | |
| 5 mM | 0.4993 mL | 2.4966 mL | 4.9931 mL | |
| 10 mM | 0.2497 mL | 1.2483 mL | 2.4966 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
